

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A)

Pichaet Wiriyaichitra^{1*}, Sirithip Wiriyaichitra¹, Siriporn Wonghiranyingyot¹, Ampai Panthong², Ganigah Ruanjahn³, Souwalak Phongpaichit⁴ and Wilawan Mahabusarakam⁴

¹Asian Phytoceuticals Public Company Limited, Thailand.

²Chiang Mai University, Thailand.

³Boromarajonani College of Nursing, Chiang Mai Thailand.

⁴Prince of Songkla University, Thailand.

*Correspondence:

Wiriyaichitra P, Asian Phytoceuticals Public Company Limited, Thailand, Tel: +662 646 4882.

Received: 05 Jan 2025; Accepted: 15 Feb 2025; Published: 25 Feb 2025

Citation: Wiriyaichitra P, Wiriyaichitra S, Wonghiranyingyot S, et al. ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A). Clin Immunol Res. 2025; 9(1): 1-5.

ABSTRACT

In the article ByeByeHIV with Thai Innovation, published on February 25, 2024, we reported the success of using ByeByeHIV innovation to achieve ByeByeHIV, a condition of undetectable HIV with good health without the use of any antiretroviral drugs. The innovation, a synergistic mixture of extracts from mangosteen, black sesame, soy, guava, and Centella asiatica, is a dietary supplement approved by the Thai FDA under the name BIM V, LIV, Mylife, and NOVIR. The formula enhances immune function by stimulating Th1 and Th17 cells, boosting killer T cell activity, and repairing telomere damage caused by HIV and antiretroviral drugs. The success was observed in two groups: the first group comprised 24 HIV-infected individuals who had never used antiretroviral drugs (Group A), and the second group included 26 individuals who were previously infected with HIV and had used antiretroviral drugs (Group B). As of December 2024 the number of successful ByeByeHIV cases in Group A increased to 40 individuals and Group B to 40 individuals. This article provides a progress update on Group A. The results showed that all 40 volunteers in Group A have achieved ByeByeHIV. Furthermore, 15 volunteers in this group have discontinued ByeByeHIV formula for periods ranging from 6 months to over 4 years and remain in good health with undetectable HIV. The first volunteer, who decided to discontinue ByeByeHIV formula after almost 7 years of undetectable HIV, has enjoyed approximately 10 years of undetectable HIV. This suggests that these 15 volunteers may have become HIV-free. A representative case, Mr. Din, has maintained undetectable HIV with good health after discontinuing ByeByeHIV formula in August 2024. The results underscore the effectiveness of ByeByeHIV formula as a therapy for individuals who have never used antiretroviral drugs, marking a significant milestone in the global fight to eradicate HIV/AIDS.

Keywords

HIV, AIDS, ByeByeHIV, HIV-free, Plant-based Immunotherapy, Mangosteen, Killer T cell, Telomere lengthening.

Introduction

ByeByeHIV is defined as the condition in which HIV/AIDS-infected individuals can reduce their HIV load to undetectable levels without the consumption of antiviral drugs and enjoy healthy living. It also refers to the condition where HIV infected individuals, who have consumed antiretroviral drugs as the

treatment but can no longer tolerate the drugs' side effects, can stop taking the drugs and enjoy living a healthy life with undetectable HIV [1].

ByeByeHIV innovation utilizes ByeByeHIV formula, which is composed of a synergistic mixture of refined extracts from 5 types of edible plants, namely mangosteen, black sesame, soy, guava, and Centella asiatica. It has been proven effective in stimulating Th1 and Th17 cells, boosting the potency of killer T cells to eliminate HIV-infected cells. It has also been shown to repair the





telomere damage caused by HIV and telomere shortening caused by the side effects of antiretroviral drugs [1]. ByeByeHIV formula has been registered with the Thai FDA as a dietary supplement under the name BIM V, LIV, Mylife, and NOVIR.









In the article *ByeByeHIV with Thai Innovation*, published on February 25, 2024, we reported the success of using ByeByeHIV innovation, a plant-based immunotherapy, to achieve undetectable HIV levels and restore normal health. This ByeByeHIV success was observed in two groups: the first group comprised 24 HIV-infected individuals who had never used antiretroviral drugs (Group A), and the second group included 26 individuals who were previously infected with HIV and had used antiretroviral drugs (Group B) [1]. As of December 2024 the number of successful ByeByeHIV cases in Group A increased to 40 individuals and Group B to 40 individuals.




Objective

The objective of this article is to provide a progress update on the conditions of the volunteers in Group A, which has expanded to include 16 additional participants, who opted not to use antiretroviral drugs and were given ByeByeHIV formula. (The progress of Group B will be reported in a subsequent article.)

These volunteers exhibited a progressive increase in CD4 levels and a decrease in HIV load. Once their CD4 levels and CD4% were boosted with ByeByeHIV formula to normal levels with undetectable HIV, they gradually reduced the dosage of ByeByeHIV formula daily intake. Some of the volunteers in this group eventually stopped taking ByeByeHIV formula after their HIV was not detected in blood tests for several months. Many months later, their monthly blood tests continued to show undetectable HIV. In total, 15 volunteers in this group have discontinued ByeByeHIV formula for periods ranging from 6 months to over 4 years and remain in good health. The first volunteer in this group, who decided to discontinue ByeByeHIV formula after almost 7 years of undetectable HIV, has enjoyed approximately 10 years of undetectable HIV. **This suggests that these 15 volunteers may have become HIV-free.** The results in Group A indicate that all of the 40 volunteers have achieved undetectable HIV without the use of any antiretroviral drugs. This marks a significant milestone in the therapy to achieve ByeByeHIV, a condition of undetectable HIV with good health, for HIV patients who have never used antiretroviral drugs. Due to limited space, the data for all 40 cases in Group A can be accessed at <https://www.byebyehiv.com> under the menu 'ByeByeHIV achieved in Thailand' and the sub-menu 'ByeByeHIV for people who have never used antivirals'. Below, we present the graphs of the 15 cases who may have become HIV-free.







The Representative Case for Group A (ByeByeHIV without Prior use of Antiretroviral Drugs): Mr. Din (Refer to the graph 'Mr. Din #7' above)

Mr. Din is an individual who has achieved ByeByeHIV and wishes to reveal his identity to demonstrate the authenticity of his success and to encourage other infected individuals to achieve the same. Currently, he works as a counselor and mentor to those seeking to achieve ByeByeHIV. He plays an important role in accelerating efforts to reduce the number of people suffering from HIV/AIDS, a key element in the global initiative to eradicate HIV/AIDS.

At the outset, Mr. Din, age 38, had an HIV viral load of 2,532,199

copies/ml, with a CD4 count of only 4 cells/cu.mm. After undergoing ByeByeHIV immunotherapy for just 7 months, he became the 7th person to achieve ByeByeHIV without prior use of antiretroviral drugs. Since August 2020, subsequent tests have shown no detectable HIV, and his overall health has returned to normal. Previous health issues, such as blood infections and skin peeling due to antibiotic allergies, were resolved. In August 2024, Mr. Din discontinued ByeByeHIV formula and has continued to do so with no detectable HIV and with good health.

Health Information of Mr. Din

- Mr. Din was diagnosed with HIV in December 2019.
- His health issues were blood infections and skin peeling due to antibiotic allergies.
- Before undergoing ByeByeHIV immunotherapy, his CD4 count was 4 cells/cu.mm, his CD4% was 0.7%, and his HIV viral load was 2,532,199 copies/ml.
- He started using ByeByeHIV immunotherapy in February 2020.
- In August 2020, after 7 months of ByeByeHIV immunotherapy, Mr. Din achieved ByeByeHIV, with no HIV detected in his blood tests and he continues to have good health.
- In August 2024, Mr. Din discontinued ByeByeHIV formula and has continued to do so with no detectable HIV and with good health.

Standard ByeByeHIV procedure for HIV-infected Individuals who have not taken Antiretrovirals (Group A)

Step 1: Test for HIV load, CD4 count and CD4%.

Step 2: Take 3-4 capsules (depending on the severity) half an hour before meals, totaling 9-12 capsules per day, while testing for HIV load, CD4 count and CD4% every 1-2 months until no infection is detected.

Step 3: Gradually reduce the number of capsules.

In the first month, reduce to 2-3 capsules, half an hour before meals, totaling 6-9 capsules a day. In the second month, take 2 capsules half an hour before breakfast and dinner, totaling 4 capsules a day. Then in the following months, reduce to 1 capsule half an hour before breakfast and dinner, totaling 2 capsules a day to maintain sufficient immunity at all times and, eventually, discontinue taking the capsule.

Conclusion

ByeByeHIV formula, a plant-based immunotherapy, represents a groundbreaking innovation that enables HIV-infected individuals to achieve undetectable HIV levels without antiretroviral drugs that come with severe side effects. The formula, a synergistic mixture of extracts from mangosteen, black sesame, soy, guava, and Centella asiatica, is approved by the Thai FDA as a dietary supplement under the name BIM V, LIV, Mylife, and NOVIR. It enhances immune function by stimulating Th1 and Th17 cells,

boosting killer T cell activity, and repairing telomere damage caused by HIV and antiretroviral drugs. ByeByeHIV formula has shown impressive efficacy in restoring immune function, reducing HIV levels and potentially eliminating HIV, thereby improving overall health.

In the article *ByeByeHIV with Thai Innovation*, published on February 25, 2024, we reported the success of using ByeByeHIV innovation to achieve ByeByeHIV, a condition of undetectable HIV with good health without the use of any antiretroviral drugs. The success was observed in two groups: the first group comprised 24 HIV-infected individuals who had never used antiretroviral drugs (Group A), and the second group included 26 individuals who were previously infected with HIV and had used antiretroviral drugs (Group B). As of December 2024 the number of successful ByeByeHIV cases in Group A increased to 40 individuals and Group B to 40 individuals. The results reported in this article showed that all 40 HIV-infected volunteers in Group A, who have never used antiretroviral drugs, have achieved ByeByeHIV, a condition of undetectable HIV with good health, without the use of any antiretroviral drugs. Furthermore, 15 volunteers in this group have discontinued ByeByeHIV formula for periods ranging

from 6 months to over 4 years and remain in good health. The first volunteer, who decided to discontinue ByeByeHIV formula after almost 7 years of undetectable HIV, has enjoyed approximately 10 years of undetectable HIV. **This suggests that these 15 volunteers may have become HIV-free.** A representative case, Mr. Din, was diagnosed with HIV in 2019 and started using ByeByeHIV formula with a CD4 count of 4 cells/cu.mm and a viral load of 2,532,199 copies/ml, and achieved undetectable HIV within 7 months. After discontinuing ByeByeHIV formula in August 2024, he has maintained undetectable HIV with good health.

The results, therefore, underscore the effectiveness of ByeByeHIV formula as a therapy for individuals who have never used antiretroviral drugs, offering hope to individuals seeking effective, sustainable solutions without the harsh side effects of antiretroviral drugs. **This progress marks a significant milestone in the global fight to eradicate HIV/AIDS.**

Reference

1. Wiriyaachitra P, Wiriyaachitra S, Wonghiranyingyot S, et al. ByeByeHIV with Thai Innovation. Clin Immunol Res. 2024; 8: 1-7.